ImmunoGen Inc (NASDAQ: IMGN) stock enjoyed a major increase of 82.8% on 11/30/23. The shares closed at $29.35. Moreover, this advance was accompanied by exceptionally high trading volume at 1053% of normal. The stock has been exceptionally strong relative to the market over the last nine months and has risen 93.0% during the last week.
Current PriceTarget Research Rating
IMGN is expected to be a major Value Builder reflecting capital returns that are forecasted to exceed the cost of capital.
ImmunoGen has a current Value Trend Rating of C (Neutral). This rating combines very contradictory signals from two proprietary PTR measures of a stock’s attractiveness. ImmunoGen has a very low Appreciation Score of 7 but a very high Power Rating of 98, producing the Neutral Value Trend Rating.
Rating Review
In light of this very positive price change we are reviewing our current Overall Rating of C. This review will be completed in the next several days.
Be the first to comment